Oncology development
Moderna Returns to Profit as Its Personalized Melanoma Vaccine Advances
Moderna’s first profitable quarter in two years coincides with positive Phase 3 melanoma results. Explore how tissue adequacy and logistics could shape access.
By Lampgen Clinical Research

3 min read · estimated
What the source reported
Moderna reported $162 million in GAAP net income for the third quarter of 2026, its first profitable quarter since 2024. Revenue rose 29% year over year to $1.31 billion. Moderna attributed most of that increase to international COVID-19 vaccine sales, including deliveries under long-term government partnerships. Research and development expenses fell 27% to $583 million. The company raised its 2026 revenue growth outlook to 15%–25%, from up to 10%. The stronger quarter gives Moderna more financial flexibility as it and Merck prepare regulatory submissions for a separate program, the investigational melanoma treatment intismeran autogene.
INTerpath-001 randomized 1,137 people after complete resection of high-risk stage IIB–IV cutaneous melanoma. Both arms received pembrolizumab. Participants also received either intismeran or placebo. Intismeran is an individualized mRNA treatment designed to help the immune system recognize targets selected from mutations in each patient’s tumor.
At a median follow-up of 24.6 months, the estimated two-year recurrence-free survival rate was 82.2% with intismeran plus pembrolizumab versus 70.0% with placebo plus pembrolizumab, a 12.2 percentage point difference. The hazard ratio for recurrence or death was 0.58 (95% CI 0.45–0.75). Estimated two-year distant metastasis-free survival was 88.5% versus 80.2%. Overall survival data remain immature.
Grade 3–5 treatment-related adverse events occurred in 14.2% of patients on the combination and 13.4% of patients on pembrolizumab plus placebo. Adverse events attributed to treatment led to discontinuation of at least one study drug in 14.0% versus 8.7%. Those figures matter in the adjuvant setting, where people are weighing treatment burden after surgery against the risk of recurrence. The findings apply to the population and regimen studied. Trials in other cancers will need to establish their own benefit and safety profiles.
What this means for trial teams
Measure the patients who fall out before randomization. At ESMO, investigators reported that 302 of 1,749 people screened (17.3%) were excluded for inadequate tumor tissue. Among the 757 assigned to the combination arm, intismeran was successfully manufactured for more than 99%. One measure describes how many people could enter the trial with usable tissue. The other describes manufacturing success in the group assigned to receive intismeran. Track both, along with what happened to patients whose samples were rejected.
Rehearse the path from pathology to pharmacy. The published workflow starts with tumor tissue and a blood sample. A laboratory checks sample quality, sequencing guides selection of tumor-specific targets, and a manufacturer makes a batch for the individual patient. During site activation, define who retrieves archival tissue, follows up on rejections, confirms receipt at each handoff and escalates a delay that could affect dosing. The study pharmacy should be able to verify the patient and batch match and reconcile shipment, storage and accountability records.
Track time and access together. The reported median time to first intismeran dose was 64 days in the Phase 3 trial. Site teams can track the steps separately to find whether a wait starts at tissue retrieval, testing, manufacturing, shipping or appointment scheduling. Compare sample adequacy and progression to dosing by referral source and site type where the data allow. For community sites, ask whether access to archival tissue, shipping capacity or travel for repeat visits changes who can complete the pathway.
Lampgen Clinical Research provides oncology CRA staffing and clinical-operations support. For individualized therapies, the relevant monitoring experience includes specimen traceability, patient-specific product accountability, and timely escalation when a protocol milestone is at risk. How reliably sites can carry out those tasks will matter as sponsors expand these studies and, if the treatment is approved, prepare for broader use.
Sources
- Moderna, third-quarter 2026 earnings and business update
- Reuters, international vaccine sales and updated outlook
- Merck and Moderna, Phase 3 INTerpath-001 efficacy, safety and study design
- ClinicalTrials.gov, INTerpath-001 (NCT05933577)
- ESMO 2026, INTerpath-001 Presidential Symposium presentation (LBA1)
- CancerNetwork, ESMO reporting on screening, manufacturing and safety
- JCO Oncology Advances, tissue-to-treatment workflow for intismeran
- Lampgen Clinical Research, oncology CRA staffing
- Lampgen Clinical Insights, participation burden and patient access